Plasmid-mediated QnrS2 determinant in an Aeromonas caviae isolate recovered from a patient with diarrhoea  by Arias, A. et al.
Plasmid-mediated QnrS2 determinant in an
Aeromonas caviae isolate recovered from a
patient with diarrhoea
A. Arias 1, C. Seral1, F. Navarro2,3, E. Miro´2, P. Coll2,3 and
F. J. Castillo1
1) Department of Microbiology, Hospital Clı´nico ‘Lozano Blesa’.
Zaragoza, 2) Servei de Microbiologia, Hospital de la Santa Creu i Sant
Pau, Barcelona and 3) Departement de Microbiologia, Universitat
Auto`noma de Barcelona, Cerdanyola del Valle`s, Spain
Abstract
A qnrS2 gene was identiﬁed in an Aeromonas caviae isolate (MICs
of ciproﬂoxacin, norﬂoxacin and oﬂoxacin >32 mg/L) from a
stool sample collected from a patient with gastroenteritis. The
analysis of the gyrA and parC genes revealed amino acid substi-
tutions Ser83-Ile and Ser80-Thr, respectively. In addition, ﬁve
out of 41 nalidixic acid-resistant Aeromonas isolates studied (26
identiﬁed as Aeromonas veronii bv sobria and 15 identiﬁed as
A. caviae) showed ciproﬂoxacin resistance. The identiﬁcation of
plasmid-mediated qnr genes outside of the Enterobacteriaceae
underlines a possible diffusion of these resistance determinants
among Gram-negative rods. This emphasizes the importance of
monitoring the emergence of these determinants as well as their
dissemination among the Aeromonadaceae.
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Plasmid-borne qnr genes currently constitute three families:
qnrA, qnrB and qnrS. These genes encode pentapeptide
repeat proteins that block the action of ciproﬂoxacin on
bacterial DNA gyrase and topoisomerase IV, resulting in
low-level quinolone resistance and providing a favourable
background for higher resistance to occur at quinolone con-
centrations that would be lethal in their absence, through
secondary changes in DNA gyrase and topoisomerase IV,
porins or efﬂux systems [1]. The plasmid-borne qnr genes
have been identiﬁed so far in Enterobacteriaceae and, recently,
and very rarely, in Vibrionaceae and Aeromonadaceae species.
It appears that Vibrio splendidus could be the progenitor of
the qnrS genes [2].
The objective of the present study was to screen for the
presence of the qnr genes in clinical nalidixic acid-resistant
Aeromonas species isolated from stools of patients with
gastrointestinal symptoms. Simultaneously, the quinolone
resistance determining regions (QRDRs) of the chromo-
some-encoded gyrA and parC genes were sequenced after
PCR ampliﬁcation using isolated whole-cell DNA.
Between 2000 and 2005, 41 nalidixic acid-resistant isolates
of Aeromonas species were collected. Identiﬁcation to the
genus level and testing of susceptibility to antibiotics was
performed using the semiautomatic WIDER I system
(Francisco Soria-Melguizo, Madrid, Spain). MICs of ciproﬂox-
acin, norﬂoxacin and oﬂoxacin (Sigma-Aldrich, St Louis,
MO,USA) were determined using the broth microdilution
method according to the CLSI guidelines [3]. Escherichia coli
ATCC 25922 was used as control strain. Dilutions of
ﬂuoroquinolones were in the range 0.12–64 mg/L, and the
results were interpreted according to CLSI M100-S18 guide-
lines [4]. Nalidixic acid and ciproﬂoxacin MIC values
for transconjugants were determined with the E-test (AB
Biodisk, Solna, Sweden).
The ﬁnal identiﬁcation of the strains was carried out using
conventional biochemical techniques and by ampliﬁcation of
the 16S rRNA genes (yielding a 1502-bp amplicon) using the
primers described by Borrell et al. [5] followed by enzymatic
digestion of the amplicons with BstSNI and MboI [6]. The
amplicons were sequenced and the sequence data compared
with those in the GenBank database using the BLAST pro-
gram (http://www.ncbi.nlm.nih.gov). The accession number
for the 16S rRNA gene sequences of the wild-type strains
used for comparative purposes were DQ298051.1 for Aero-
monas caviae, EF631963.1 for Aeromonas veronii bv. sobria and
FJ233864.1 for Aeromonas veronii bv veronii. Analysis of the
gyrB gene has provided an excellent molecular marker for
phylogenetic inference in the genus Aeromonas. In the present
study, the gyrB gene of qnrS-positive strain was analysed
to conﬁrm 16S rRNA gene-based identiﬁcation [7]. The
accession number for the wild-type gyrB sequence used for
comparison was EF064800.
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The qnrS gene was detected in all strains using PCR with a
set of speciﬁc primers to give a 428-bp product [8]. Screening
of the qnrA and qnrB genes was performed by PCR (Table 1).
The mutational alterations in the QRDRs were also detected
using PCR with the primers previously described [9]. The
QRDR sequences obtained for gyrA and parC were compared
with the sequences of the A. caviae complex (GenBank acces-
sion numbers AY027899 and AF435418, respectively), and of
the A. sobria complex (GenBank accession numbers
AY027900 and AF435420, respectively).
Filter mating experiments were performed in qnr-positive
isolate using a susceptible clinical E. coli as the recipient.
Transconjugants were selected on MacConkey agar plates
containing nalidixic acid (1 mg/L) and tested for qnrS by PCR.
Among the 41 nalidixic acid-resistant clinical isolates of
Aeromonas spp., 26 were identiﬁed as A. veronii bv sobria and
15 as A. caviae. Eleven isolates showed intermediate suscepti-
bility to ciproﬂoxacin (MIC = 2 mg/L), six showed resistance
to ciproﬂoxacin (MICs ‡ 4 mg/L), and only one showed
resistance to ciproﬂoxacin, norﬂoxacin and oﬂoxacin with
MIC values >64 mg/L. We did not ﬁnd any nalidixic acid-sus-
ceptible Aeromonas spp. that showed decreased susceptibility
to ciproﬂoxacin indicative of harbouring a qnr gene.
The PCR results of qnrS gene detection showed that only
one Aeromonas spp. isolate was positive. The deduced amino
acid sequence showed 100% identity with that of the QnrS2
protein (ACA29528) described in Aeromonas punctata subsp.
punctata and Aeromonas media isolates from water samples
collected from the Seine River in Paris [2]. The qnrS2 gene
was also identiﬁed on a transferable plasmid (pGNB2) iso-
lated from an activated sludge bacterial community of a
wastewater treatment plant in Germany and in a nontyphi
Salmonella isolate from the USA [2]. No qnrA and qnrB genes
were detected. The qnrS2-positive isolate was identiﬁed as
A. caviae.
Quinolone resistance was transferred by conjugation. PCR
experiments conﬁrmed that the transconjugants harboured
the same qnr gene as the donor strain. Antibiotic susceptibil-
ity testing of the transconjugants showed that the nalidixic
acid and ciproﬂoxacin MIC values increased from 0.004 mg/L
to 0.008 mg/L and from 0.75 mg/L to 1.5 mg/L, respectively.
The results obtained from the analysis of the QRDR of
gyrA and parC are shown in Table 2. The resistance to nali-
dixic acid is the result of an alteration in the QRDR of GyrA
[9]. Ciproﬂoxacin resistance could be the result of an addi-
tional alteration in the QRDR of ParC, and perhaps contrib-
ute an additive effect to that of the presence of the Qnr
determinant. Other plasmid-mediated resistance mechanisms,
such as AAC(6)-Ib-cr production and active efﬂux mediated
by QepA, have been suggested for high levels of resistance
[10] but have not been studied in these isolates.
There are very few studies of plasmid-borne qnrS determi-
nants in nonenterobacterial species. In addition to the qnrS2
gene of the two A. punctata subsp. punctata and A. media iso-
lates from the Seine River in Paris [2], a qnrS2 gene has
recently been identiﬁed in a single Aeromonas allosaccharophila
isolate from Lake Lugano in Switzerland [11]. A clinical iso-
late of A. veronii carrying qnrS2 has been described for the
ﬁrst time in Barcelona, Spain [12]. The present study identi-
ﬁed a plasmid-borne qnrS2 in an A. caviae isolate from a stool
sample collected from a patient with gastroenteritis. To our
knowledge, this is the ﬁrst identiﬁcation of a plasmid-borne
qnrS gene in a clinical isolate of A. caviae. Further spread of
this resistance determinant among Aeromonadaceae may
occur in the near future.
Identiﬁcation of qnrS genes in clinical Aeromonas spp. indi-
cates that those bacterial species may play a role as the res-
ervoir of these genes, not only in an aquatic environment.
However, whether Aeromonas species are the main or an
accessory reservoir of plasmid-mediated quinolone resistance
TABLE 1. Primers used in the
present studyPrimer Sequence (5¢ to 3¢) Gene
Size of PCR-ampliﬁed
product (bp) Reference
QnrSm-F GCAAGTTCATTGAACAGGGT qnrS1 to qnrS2 428 Cattoir et al. [8]
QnrSm-R TCTAAACCGTCGAGTTCGGCG qnrS1 to qnrS2 Cattoir et al. [8]
QnrS2F TGGAAACCTACCGTCACACA qnrS1 to qnrS2 602 Present study
QnrS2R CTGGCAATTTTGATACCTGA qnrS1 to qnrS2 Present study
QnrA-F AGAGGATTTCTCACGCCAGG qnrA 580 Cattoir et al. [8]
QnrA-R TGCCAGGCACAGATCTTGAC qnrA Cattoir et al. [8]
QnrB-F GGAATCGAAATTCGCCACTG qnrB 264 Cattoir et al. [8]
QnrB-R TTTGCCGTCCGCCAGTCGAA qnrB Cattoir et al. [8]
TABLE 2. Mutations in quinolone resistance-determining
regions and MICs of ﬂuoroquinolones for Aeromonas isolates







1 Ser83-Ile Ser80-Thr 256 >64
5 Ser83-Ile Ser80-Arg 64–256 0.5–2
13 Ser83-Ile Ser80-Ile 32–512 <0.12–64
4 Ser83-Val – 128–512 1–4
3 Ser83-Arg – 128–1024 <0.12–64
15 Ser83-Ile – 32–512 <0.12–64
NAL, nalidixic acid; CIP, ciproﬂoxacin.
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determinants in regard to Enterobacteriaceae remains to be
determined. For Aeromonas spp. to act as a reservoir of qnr
genes, they must be capable of acquiring these determinants
from their progenitors [13] and of transferring this genetic
information to Enterobacteriaceae. Because Aeromonas are
ubiquitous in a wide range of environments, they might act
as important vectors for the transfer of plasmid-mediated
quinolone resistance [14].
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Abstract
Three isolates of Mycoplasma amphoriforme, a new Mycoplasma
species rarely described to date, were obtained from respiratory
tract specimens from two children and one adult with respira-
tory tract infections. Molecular methods were required to dis-
tinguish them from Mycoplasma pneumoniae. MICs of macrolides,
tetracyclines and ﬂuoroquinolones were identical to those for
M. pneumoniae, except for that of ciproﬂoxacin, which was
slightly more potent against M. amphoriforme. M. amphoriforme
could possibly have been involved in one case of severe respira-
tory infection with sepsis, but further studies are needed to
specify its role as a potential respiratory tract pathogen.
Keywords: Human mycoplasma, molecular detection,
Mycoplasma amphoriforme, respiratory tract infection,
susceptibility testing
Original Submission: 14 April 2009; Revised Submission:
24 June 2009; Accepted: 3 July 2009
Editor: D. Raoult
Article published online: 23 September 2009
Clin Microbiol Infect 2010; 16: 1007–1009
10.1111/j.1469-0691.2009.02993.x
Corresponding author and reprint requests: S. Pereyre,
Laboratoire de Bacte´riologie EA 3671, Mycoplasma and Chlamydia
Infections in Humans, Universite´ Victor Segalen Bordeaux 2, 146 rue
Le´o Saignat, 33076 Bordeaux Cedex, France
E-mail: sabine.pereyre@u-bordeaux2.fr
CMI Research Notes 1007
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1005–1030
